OTCPK:MYDP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dougherty’s Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Dougherty's Pharmacy's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYDP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

MYDP

1.4%

US Consumer Retailing

2.8%

US Market


1 Year Return

-94.7%

MYDP

16.1%

US Consumer Retailing

9.3%

US Market

Return vs Industry: MYDP underperformed the US Consumer Retailing industry which returned 16.2% over the past year.

Return vs Market: MYDP underperformed the US Market which returned 9.9% over the past year.


Shareholder returns

MYDPIndustryMarket
7 Day0%1.4%2.8%
30 Day5.9%1.8%8.9%
90 Day-11.3%4.0%-0.5%
1 Year-94.7%-94.7%18.2%16.1%11.8%9.3%
3 Year-94.8%-94.8%37.8%29.9%31.4%22.7%
5 Year-95.9%-95.9%60.3%43.7%58.7%40.9%

Price Volatility Vs. Market

How volatile is Dougherty's Pharmacy's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dougherty's Pharmacy undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: MYDP ($0.01) is trading above our estimate of fair value ($0)

Significantly Below Fair Value: MYDP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MYDP is unprofitable, so we can't compare its PE Ratio to the Consumer Retailing industry average.

PE vs Market: MYDP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYDP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYDP has negative assets, so we can't compare its PB Ratio to the US Consumer Retailing industry average.


Next Steps

Future Growth

How is Dougherty's Pharmacy forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

7.1%

Forecasted Consumer Retailing industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dougherty's Pharmacy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MYDP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Dougherty's Pharmacy's filings and announcements here.
  • Explore growth companies in the Consumer Retailing industry.

Past Performance

How has Dougherty's Pharmacy performed over the past 5 years?

-70.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: MYDP is currently unprofitable.

Growing Profit Margin: MYDP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if MYDP's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare MYDP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYDP is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (4.1%).


Return on Equity

High ROE: MYDP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Dougherty's Pharmacy's financial position?


Financial Position Analysis

Short Term Liabilities: MYDP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MYDP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MYDP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MYDP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MYDP has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MYDP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Dougherty's Pharmacy's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYDP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYDP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Stewart Edington (50yo)

1.33yrs

Tenure

Mr. Stewart I. Edington serves as Chief Executive Officer at Dougherty's Pharmacy, Inc. Mr. Edington served as President and Interim Chief Financial Officer at Dougherty's Pharmacy, Inc. since February 07 ...


Leadership Team

NamePositionTenureCompensationOwnership
James Leslie
Chairman of the Board18.25yrsUS$101.18k7.92% $16.5k
Stewart Edington
Chief Executive Officer1.33yrsno datano data
Katherine Burrow
Managing Director of Business Development2.33yrsno datano data
Susan Olson
Secretaryno datano datano data
Robin Bruce
Controllerno datano datano data
Rick Troberman
Executive Vice President of Sales and Marketingno datano datano data

2.3yrs

Average Tenure

Experienced Management: MYDP's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Leslie
Chairman of the Board18.25yrsUS$101.18k7.92% $16.5k
Anthony LeVecchio
Independent Director16yrsUS$22.68k1.57% $3.3k
Will Cureton
Independent Director15.42yrsUS$13.18k0.27% $564.1
Troy Phillips
Independent Director2.83yrsUS$12.00k17.31% $36.0k

15.7yrs

Average Tenure

70yo

Average Age

Experienced Board: MYDP's board of directors are seasoned and experienced ( 15.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Dougherty's Pharmacy, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dougherty's Pharmacy, Inc.
  • Ticker: MYDP
  • Exchange: OTCPK
  • Founded: 1929
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Market Cap: US$207.881k
  • Shares outstanding: 23.10m
  • Website: https://www.doughertys.com

Number of Employees


Location

  • Dougherty's Pharmacy, Inc.
  • 5924 Royal Lane
  • Suite 250
  • Dallas
  • Texas
  • 75230
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYDPOTCPK (Pink Sheets LLC)YesClass A Common StockUSUSDNov 1999

Biography

Dougherty’s Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. Its flagship store is Dougherty’s Pharmacy, a turn-key multi-service pharmacy located in Dallas, Texas. The company was formerly known as Ascendant Solutions, Inc. and changed its name to Dougherty’s Pharmacy, Inc. in May 2017. Dougherty’s Pharmacy, Inc. was founded in 1929 and is based in Dallas, Texas. On August 28, 2019, Dougherty's Pharmacy, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with Dougherty's Holdings, Inc.  


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 11:17
End of Day Share Price2020/05/29 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.